Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pathologic Stage IV Cutaneous Melanoma AJCC v8: early-phase trial registry
4 of 10 indexed Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Pathologic Stage IV Cutaneous Melanoma AJCC v8: 10 US clinical trials tracked, 4 recruiting.
Pathologic Stage IV Cutaneous Melanoma AJCC v8 is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition pathologic-stage-iv-cutaneous-melanoma-ajcc-v8
OPEN 4 | RECR 40% | LATE 0 | EARLY 9 | RANK #1724 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Pathologic Stage IV Cutaneous Melanoma AJCC v8 lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pathologic Stage IV Cutaneous Melanoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pathologic Stage IV Cutaneous Melanoma AJCC v8 is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pathologic Stage IV Cutaneous Melanoma AJCC v8 research.
M.D. Anderson Cancer Center accounts for 4 of 10 trials (40%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 10 trials that report a genuine target (sentinel values excluded). 8 of those (80%) plan for fewer than 100 participants.
-
Pathologic Stage IV Cutaneous Melanoma AJCC v8 research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
NCT04511013
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
NCT05026983
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Kari Kendra
NCT05588453
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT04462406
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT04645680
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT01644591
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT03175432
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT05341349
The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients
Ohio State University Comprehensive Cancer Center
NCT05102773
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Pathologic Stage IV Cutaneous Melanoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pathologic Stage IV Cutaneous Melanoma AJCC v8 page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Pathologic Stage IV Cutaneous Melanoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pathologic Stage IV Cutaneous Melanoma AJCC v8 condition card totals 10 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.